Literature DB >> 2169938

Pharmacological and biochemical effects of the cardiotonic agent Org10325 in isolated cardiac and vascular tissue preparations.

M Shahid1, M G Martorana, J E Cottney, R J Marshall.   

Abstract

1. The pharmacological and biochemical effects of a novel cardiotonic agent, Org10325 have been studied in isolated cardiac and vascular tissue preparations. 2. Org10325 produced concentration-dependent (0.15-4.8 mM) positive inotropic, positive chronotropic and vascular relaxant responses in rabbit isolated papillary, atrial and aortic preparations, respectively. The maximal chronotropic effect (45%) was significantly less than the isoprenaline maximum. The inotropic effects of Org10325 were not modified by alpha- or beta-adrenoceptor blockade or by pretreatment with reserpine. Org10325 was at least 23 times more potent at relaxing aortic strips pre-contracted with phenylephrine than with KCl. 3. Org10325 (74 microM) potentiated (10-14 fold) the positive inotropic effects of isoprenaline in rabbit isolated papillary muscles. Carbachol inhibited the positive inotropic effect of Org10325. Both the positive inotropic and vasorelaxant effects of Org10325 were accompanied by increases in cyclic AMP but not cyclic GMP. 4. In rat perfused heart preparation Org10325 increased phosphorylase a, cyclic AMP-dependent protein kinase activities and stimulated phosphorylation of contractile proteins (troponin-I and C-protein). 5. Org10325 selectively inhibited the cyclic AMP hydrolytic activity of cyclic AMP high affinity cyclic nucleotide phosphodiesterase (PDE) isoenzymes, PDE III (IC50 65 microM) and PDE IV (IC50 71 microM), from rabbit cardiac ventricle. Weak inhibition (IC50 greater than 250 microM) of PDE I and PDE II was observed. 6. The results show that the cardiac and vascular effects of Org10325 are mediated by an increase in cellular cyclic AMP due to inhibition of PDE III and PDE IV activities. However, in contrast to other PDE-inhibitors OrglO325 produced a marked increase in relaxation time of isolated papillary muscle suggesting the involvement of additional cyclic AMP-independent mechanisms of action.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2169938      PMCID: PMC1917585          DOI: 10.1111/j.1476-5381.1990.tb14084.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  31 in total

1.  Interaction between cyclic adenosine monophosphate and cyclic gunaosine monophosphate in guinea pig ventricular myocardium.

Authors:  A M Watanabe; H R Besch
Journal:  Circ Res       Date:  1975-09       Impact factor: 17.367

2.  The stimulation of calcium uptake into sarcoplasmic-reticulum vesicles from rat heart by adenosine 3',5'-phosphate-dependent protein kinase [proceedings].

Authors:  D N Hollinworth; P J England
Journal:  Biochem Soc Trans       Date:  1978       Impact factor: 5.407

3.  Rate of calcium binding and uptake in normal animal and failing human cardiac muscle. Membrane vesicles (relaxing system) and mitochondria.

Authors:  S Harigaya; A Schwartz
Journal:  Circ Res       Date:  1969-12       Impact factor: 17.367

4.  The time course of changes in cyclic nucleotide levels during cholinergic inhibition of positive inotropic actions of isoprenaline and theophylline in the isolated canine ventricular myocardium.

Authors:  M Endoh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-06       Impact factor: 3.000

Review 5.  Role of cyclic nucleotides in heart metabolism.

Authors:  L H Opie
Journal:  Cardiovasc Res       Date:  1982-09       Impact factor: 10.787

6.  Chronotropic and inotropic actions of amrinone, carbazeran and isobutylmethyl xanthine: role of phosphodiesterase inhibition.

Authors:  M Shahid; I W Rodger
Journal:  Br J Pharmacol       Date:  1989-09       Impact factor: 8.739

7.  The metabolism of cyclic nucleotides in the guinea-pig pancreas. Cyclic AMP phosphodiesterase and cyclic GMP phosphodiesterase.

Authors:  P Methven; M Lemon; K Bhoola
Journal:  Biochem J       Date:  1980-02-15       Impact factor: 3.857

8.  Current therapy of acute heart failure.

Authors:  G F Rettig; L Bette
Journal:  Cardiovasc Drugs Ther       Date:  1988-11       Impact factor: 3.727

9.  The relation between the effects of veratridine on action potential and contraction in mammalian ventricular myocardium.

Authors:  P Honerjäger; M Reiter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1975       Impact factor: 3.000

10.  The role of cyclic AMP and the dihydropyridine-sensitive channels on the mechanism of action of milrinone (Corotrope).

Authors:  C J Frangakis; C Lanni; K P Lasher; R G Bentley; A E Farah
Journal:  J Cardiovasc Pharmacol       Date:  1989-06       Impact factor: 3.105

View more
  1 in total

Review 1.  Oximes: Novel Therapeutics with Anticancer and Anti-Inflammatory Potential.

Authors:  Igor A Schepetkin; Mark B Plotnikov; Andrei I Khlebnikov; Tatiana M Plotnikova; Mark T Quinn
Journal:  Biomolecules       Date:  2021-05-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.